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Abstract
Colorectal cancer is one of the most common types of cancer with over fifty percent of patients presenting at an advanced
stage. Retinoic acid is a metabolite of vitamin A and is essential for normal cell growth and aberrant retinoic acid
metabolism is implicated in tumourigenesis. This study has profiled the expression of retinoic acid metabolising enzymes
using a well characterised colorectal cancer tissue microarray containing 650 primary colorectal cancers, 285 lymph node
metastasis and 50 normal colonic mucosal samples. Immunohistochemistry was performed on the tissue microarray using
monoclonal antibodies which we have developed to the retinoic acid metabolising enzymes CYP26A1, CYP26B1, CYP26C1
and lecithin retinol acyl transferase (LRAT) using a semi-quantitative scoring scheme to assess expression. Moderate or
strong expression of CYP26A1was observed in 32.5% of cancers compared to 10% of normal colonic epithelium samples
(p,0.001). CYP26B1 was moderately or strongly expressed in 25.2% of tumours and was significantly less expressed in
normal colonic epithelium (p,0.001). CYP26C1 was not expressed in any sample. LRAT also showed significantly increased
expression in primary colorectal cancers compared with normal colonic epithelium (p,0.001). Strong CYP26B1 expression
was significantly associated with poor prognosis (HR = 1.239, 95%CI = 1.104–1.390, x2 = 15.063, p = 0.002). Strong LRAT was
also associated with poorer outcome (HR= 1.321, 95%CI = 1.034–1.688, x2 = 5.039, p = 0.025). In mismatch repair proficient
tumours strong CYP26B1 (HR = 1.330, 95%CI = 1.173–1.509, x2 = 21.493, p,0.001) and strong LRAT (HR = 1.464,
95%CI = 1.110–1.930, x2 = 7.425, p = 0.006) were also associated with poorer prognosis. This study has shown that the
retinoic acid metabolising enzymes CYP26A1, CYP26B1 and LRAT are significantly overexpressed in colorectal cancer and
that CYP26B1 and LRAT are significantly associated with prognosis both in the total cohort and in those tumours which are
mismatch repair proficient. CYP26B1 was independently prognostic in a multivariate model both in the whole patient
cohort (HR = 1.177, 95%CI = 1.020–1.216, p = 0.026) and in mismatch repair proficient tumours (HR= 1.255, 95%CI = 1.073–
1.467, p = 0.004).
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Introduction
Colorectal cancer is one of the commonest types of malignancy
whose 5 year survival remains at approximately fifty percent
despite the introduction of bowel cancer screening programmes
[1]. While the molecular pathogenesis of this type of tumour is
increasingly being understood and defined especially the early
stages of colorectal cancer development where the molecular
changes have been delineated with a high degree of detail [2–4].
However, there is still a clear need to identify biomarkers of
colorectal cancer including prognostic, predictive and diagnostic
markers [5–15].
Retinoic acid (RA) is a metabolite of vitamin A (retinol), which
performs essential functions in normal cell growth and differen-
tiation and dysregulated retinoic acid metabolism has been
implicated in tumourigenesis [16,17]. Retinoids, a term used to
describe natural or synthetic compounds showing a structural or
functional resemblance to retinol, have prominent roles to play in
cell growth, differentiation and apoptosis [16]. The most active
form of RA, all-trans retinoic acid (atRA), has a gene regulatory
function and plays a crucial role in development of the multiple
organs. 4-oxo-9-cis-retinoic acid (9-cis-RA) and 4-oxo-13-cis-
retinoic acid (13-cis-RA) are stereo-isomers of atRA and also play
an important role in RA signalling. Some retinoids possess anti-
cancer properties that have already been exploited for the
treatment of several types of cancer including cervical cancer
and promyelocytic leukaemia.
The intracellular processing of retinol involves lecithin retinol
acyl transferase (LRAT) which is responsible for the esterification
of retinol [18,19] while hydroxylation of retinol is performed by
the retinoic acid hydroxylases (CYP26A1, CYP26B1, CYP26C1)
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which are all members of the cytochrome P450 (P450) family of
enzymes [20,21].
The three members of the CYP26 family are all capable of
metabolising atRA into less biologically active 4-hydroxy-, 4-oxo-,
and 18-hydroxy-RA intermediates [22–24], of which, 4-oxo-RA is
the most common metabolite [16]. Although previous studies have
investigated P450 expression in tumours and shown tumour
selective expression of individual P450s most notably CYP1B1
[25] the CYP26 family of P450s has received little prior attention
in relation to their expression in tumours.
This study has profiled the expression of the retinoic acid
metabolising enzymes CYP26A1, CYP26B1, CYP26C1 and
LRAT using a well characterised colorectal cancer tissue
microarray with monoclonal antibodies to CYP26A1, CYP26B1,
CYP26C1 and LRAT respectively, that have been developed and
characterised for their use by immunohistochemistry on formalin
fixed wax embedded tissue.
Materials and Methods
Monoclonal antibodies
Monoclonal antibodies to CYP26A1, CYP26B1, CYP26C1 and
LRAT were developed in collaboration with Vertebrate Antibod-
ies Ltd (Aberdeen, UK) using synthetic peptides. Peptides within
the putative protein sequences were identified which were
antigenic, exposed on the surface and unique to the target protein.
The amino acid sequences and location on the proteins are
indicated in table 1. The peptides were obtained from Almac
Sciences Ltd, (Edinburgh, UK) and conjugated individually to
ovalbumin for the immunisations and to bovine serum albumin for
the ELISA tests [26]. The immunisation of mice, production of
hybridoma cells and ELISA screening were carried out essentially
as described previously [26] except that the antigen was given by
subcutaneous route. The hybridomas were cloned by limiting
dilution until a single ELISA positive colony was grown in a 96
well plate. Individual cell lines were then grown at high cell density
for the preparation of the antibody stock which was used
subsequently for their characterisation by immunoblotting and
immunohistochemistry.
Immunoblotting
Whole cell lysates from cells (human embryonic kidney cells)
overexpressing CYP26A1, CYP26B1, CYP26C1 and LRAT were
used as positive controls for immunoblotting while lysates from
cells containing vector only were used as negative controls. The
CYP26A1 cell lysate and its control were purchased from Abnova
(Taipei, Taiwan) while CYP26B1, CYP26C1 and LRAT contain-
ing cell lysates and their corresponding controls were obtained
from (Novus Biologicals, Cambridge, UK). Cell lysates (5 mg
protein/lane) were resolved by electrophoresis on NuPAGE 4-
12% bis-Tris gels (Fisher Scientific, Loughborough, UK). Follow-
ing protein transfer the membranes were blocked for 1 hour at
room temperature in phosphate buffered saline-Tween-20 (PBST)
containing 1% (w/v) skimmed milk powder. Membranes were
incubated overnight at 4uC with CYP26A1 (1/5 dilution),
CYP26B1 (1/2 dilution), CYP26C1 (1/2 dilution) or LRAT
(1/2 dilution) monoclonal antibodies diluted in PBST. Membranes
were washed (6 times) for 1 hour in 1% skimmed milk. The
membranes were subsequently probed for 1 hour with a secondary
antibody conjugated horseradish-peroxidase-conjugated anti-
mouse IgG (1/2000, Sigma-Aldrich, Dorset, UK). Membranes
were then washed (6 times) for 1 hour in 1% skimmed milk and
protein bands visualized using the enhanced chemiluminescence
detection system (Fisher Scientific).
Colorectal cancer tissue microarray
All cases of colorectal cancer included in this study were
retrospectively selected from the Aberdeen colorectal tumour bank
(now incorporated in and governanced by the NHS Grampian
Biorepository, Aberdeen, UK). In total, tumour samples from 650
patients were involved in this study, in each case, a diagnosis of
primary colorectal cancer had been made, and the patients had
undergone elective surgery for primary colorectal cancer, in
Aberdeen, between 1994 and 2009. None of the patients had
received any form of pre-operative chemotherapy or radiotherapy.
In particular patients with rectal cancer who had received
neoadjuvant therapy including short course radiotherapy were
excluded. The data for the patients and their tumours included in
this study is detailed in Table S1. Survival information (all cause
Table 1. Details of amino acid sequences used as peptide
immunogens.
Enzyme Amino acid sequence Location of peptide
CYP26A1 PARFTHFHGE 487–496
CYP26B1 DSNQNEILPE 494–503
CYP26C1 RWELATPAFP 481–490
LRAT RDQRSVLASA 190–199
doi:10.1371/journal.pone.0090776.t001
Figure 1. Immunoblots of CYP26A1, CYP26B1, CYP26C1 and LRAT antibodies. The left hand lane of each panel contains control cell lysate
while the right hand lane of each panel contains lysate prepared from cells over expressing the relevant protein. 5 micrograms of protein were loaded
per well.
doi:10.1371/journal.pone.0090776.g001
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Figure 2. Photomicrographs of CYP26A1, CYP26B1, CYP26C1 and LRAT in normal colonic mucosa, primary colorectal cancer and
metastatic colorectal cancer.
doi:10.1371/journal.pone.0090776.g002
Figure 3. The frequency distribution of the intensity of expression of CYP26A1, CYP26B1, CYP26C1 and LRAT in normal colonic
mucosa, primary colorectal cancer and metastatic colorectal cancer.
doi:10.1371/journal.pone.0090776.g003
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mortality) was available for all patients and at the time of censoring
patient outcome data there had been 309 (47.5%) deaths. The
mean patient survival was 115 months (95% CI 108–123 months).
The tumours were reported according to The Royal College of
Pathologists UK guidelines for the histopathological reporting of
colorectal cancer resection specimens and which incorporates
guidance from version 5 of the TNM staging system [27]. The
histopathological processing of the colorectal cancer excision
specimens is detailed in Materials and Methods S1.
A colorectal cancer tissue microarray was constructed contain-
ing normal colon mucosal samples (n = 50), primary (n = 650) and
metastatic colorectal cancer samples (n = 285) as previously
described [28–30]. Details of the construction of the tissue
microarray are given in Materials and Methods S1.
Immunohistochemistry
Immunohistochemistry for each antibody was performed with
the biotin-free Dako Envision system (Dako, Ely, UK) using a
Dako autostainer (Dako) as previously described [28–30]. Details
of the immunohistochemistry are given in Materials and Methods
S1. The sections were evaluated by light microscopic examination
and the intensity of immunostaining in each core assessed
independently by two investigators (GTB and GIM) using a
scoring system previously described for the assessment of protein
expression in tumour microarrays [28–30]. The intensity of
immunostaining in each core was scored as negative, weak,
moderate or strong. The sub-cellular localisation (nuclear,
cytoplasmic or membranous) of the immunostaining was also
recorded. Variation in immunostaining between cores of each case
was not identified. Any discrepancies in the immunohistochemical
assessment of the tissue cores between the two observers were
resolved by simultaneous microscopic re-evaluation.
Assessment of mismatch repair status
Mismatch repair status (MMR) was assessed by immunohisto-
chemistry using antibodies to MLH1 and MSH2 as described
previously [28,30]. MMR status was recorded as either proficient
or defective.
Statistics
Statistical analysis of the data including the Mann-Whitney U
test, Wilcoxon signed rank test, chi-squared test, Kaplan-Meier
survival analysis, log-rank test and Cox multi-variate analysis
(variables entered as categorical variables) including the calcula-
tion of hazard ratios and 95% CIs was performed using IBM SPSS
version 21 for Windows 7TM (IBM, Portsmouth, UK). The log
rank test was used to determine survival differences between
individual groups. A probability value of p#0.05 was regarded as
significant. The influence of different cut-off points in relation to
survival was investigated by dichotomizing the intensity score for
each marker. The groups that were analysed were negative
staining versus any positive staining, negative and weak staining
versus moderate and strong staining and negative, weak and
moderate staining versus strong staining.
Ethics
The project had the approval of The North of Scotland research
ethics committee (ref. nos. 08/S0801/81 and 11/NS/0015). The
research ethics committee did not require written patient consent
Table 2. Comparison of CYP26A1, CYP26B1 and LRAT expression in normal colonic mucosa, primary colorectal cancer and lymph
node metastasis.
Immunoreactivity (p
value, normal versus
primary tumour)
Change in
expression in
tumour
Immunoreactivity
(p value, primary
tumour versus lymph
node metastasis)
Change in
expression in
lymph node
Immunoreactivity
(p value, paired primary
Dukes C tumour versus
lymph node metastasis)
Change in
expression in
lymph node
CYP26A1 0.002 q 0.015 Q 0.208 «
CYP26B1 ,0.001 q 0.822 « 0.656 «
CYP26C1 - - - - - -
LRAT ,0.001 q ,0.001 Q ,0.001 Q
Evaluation of normal colonic epithelium versus primary tumour samples for immunoreactivity (Mann-Whitney U test, q= increased in tumour, Q=decreased in
tumour, - = no change between tumour and normal) and evaluation of primary Dukes C colorectal tumour samples and their corresponding metastasis samples for
immunoreactivity (Wilcoxon signed rank sum test,q= increased in lymph node metastasis,Q=decreased in lymph node metastasis,«=no change between primary
and metastatic tumour). Significant values are highlighted in bold.
doi:10.1371/journal.pone.0090776.t002
Table 3. The relationship of CYP26A1, CYP26B1 and LRAT with pathological parameters.
Tumour site
Tumour
differentiation pT stage pN stage Dukes stage EMVI MMR status
Bowel screen
detected
x2 p value x2 p value x2 p value x2 p value x2 p value x2 p value x2 p value x2 p value
CYP26A1 13.000 0.043 1.625 0.654 15.728 0.073 9.476 0.136 11.545 0.073 3.03 0.387 0.613 0.894 1.367 0.713
CYP26B1 25.723 0.002 1.760 0.624 25.723 0.002 10.743 0.097 21.000 0.002 8.839 0.032 1.649 0.648 5.192 0.158
CYP26C1 - - - - - - - - - - - - - - -
LRAT 29.861 ,0.001 3.815 0.282 29.861 ,0.001 3.073 0.800 22.208 0.001 8.563 0.036 1.198 0.754 5.624 0.131
Significant values are highlighted in bold.
doi:10.1371/journal.pone.0090776.t003
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Figure 4. The relationship of CYP26B1 and survival. A–D whole patient cohort. A. overall survival showing individual CYP26B1 categories. In
B–D the influence of different cut of points is shown. E–H Mismatch repair proficient cohort. E. overall survival showing individual CYP26B1
categories. In F–H the influence of different cut-off points is shown.
doi:10.1371/journal.pone.0090776.g004
CYP26 and Colorectal Cancer
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for the retrospective tissue samples that were included in the
colorectal cancer tissue microarray.
Results
Monoclonal antibodies
The specificity of the monoclonal antibodies to CYP26A1,
CYP26B1, CYP26C1 and LRAT were determined by ELISA
using the immunogenic peptides and also by immunoblotting
(figure 1) using whole cell lysates from cells overexpressing each
protein. A band migrating at the expected molecular weight was
observed for each antibody in a lysate prepared from cells
overexpressing the relevant protein while no bands were detected
with the corresponding control lysate.
Immunohistochemistry
CYP26A1, CYP26B1 and LRAT all showed immunoreactivity
in both normal colonic epithelium and primary and metastatic
colorectal cancer and in each case immunostaining was localised
to the cytoplasm of cells (figure 2). There was no nuclear or cell
surface membrane imunoreactivity. In normal colonic epithelium
immunostaining was predominantly localised surface epithelial
cells and no intratumour heterogeneity was observed in either
primary or metastatic colorectal tumours. CYP26C1 did not show
any immunostaining in any of the tissue samples examined.
The intensity of immunostaining was significantly higher in
primary colorectal cancer compared with normal colonic mucosa
for CYP26A1 (p= 0.002), CYP26B1 (p,0.001) and LRAT
(p,0.001) (figure 3, table 2). There was no difference in the
intensity of expression of either CYP26A1 or CYP26B1 between
Dukes C colorectal cancer and their corresponding lymph node
metastasis whereas for LRAT there was a significant decrease in
immunoreactivity in the lymph node metastasis compared with the
corresponding primary tumours (p,0.001) (figure 3 and table 2).
The expression of CYP26A1 was strongly correlated with both
CYP26B1 expression (x2 = 192.2, p,0.001) and LRAT expression
(x2 = 89.54, p,0.001) while CYP26B1 expression also correlated
with the expression of LRAT (x2 = 144.88, p,0.001).
Relationship with clinico-pathological parameters
Comparisons of the expression of CYP26A1, CYP26B1 and
LRAT and clinico-pathological parameters are summarised in
table 3. CYP26B1 and LRAT both showed significant associations
with tumour site, tumour (T) stage, extramural venous invasion
and overall stage. In contrast, CYP26A1 only showed a
relationship with tumour site and did not show a relationship
with any of the other clinico-pathological parameters investigated.
Survival analysis
Whole patient cohort. The relationship of the expression of
CYP26A1, CYP26B1 and LRAT with overall survival was
investigated using different cut-off points (negative v weak v
moderate v strong, negative v positive, negative/weak positive v
moderate/strong and negative/weak/moderate v strong) of the
immunohistochemical scoring and is summarised in table 4 and
figure 4.
There was a consistent and significant association between
CYP26B1 expression and outcome (Figure 4). Considering each
CYP26B1 intensity group separately, increasing intensity of
CYP26B1 immunoreactivity was associated with poorer prognosis
(HR=1.239, 95%CI= 1.104–1.390, x2 = 15.063, p = 0.002). For
CYP26B1 negative tumours (n = 242) the mean survival was 133
months (95%CI= 118–148 months), for CYP26B1 weak express-
ing tumours (n = 216) the mean survival was 106 months
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Figure 5. The relationship of LRAT and survival. A. The relationship of LRAT and survival in all colorectal cancers and B. The relationship of
LRAT and survival in mismatch repair proficient tumours.
doi:10.1371/journal.pone.0090776.g005
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(95%CI=95–116 months), for CYP26B1 moderate expressing
tumours (n = 106) the mean survival was 103 months
(95%CI=85–120 months) and for strongly expressing CYP26B1
tumours (n = 58) the mean survival was 81 months (95%CI= 60–
101 months).
Comparing CYP26B1 negative tumours with tumours that
showed any CYP26B1 immunoreactivity then poorer survival was
associated with CYP26B1 expression (HR=1.352, 95%CI=
1.054–1.735, x2 = 5.707, p = 0.017). For CYP26B1 negative
tumours (n = 242) the mean survival was 133 months
(95%CI=118–148 months) while for CYP26B1 positive tumours
(n = 380) the mean survival was 107 months (95%CI=98–116
months). Comparing CYP26B1 negative and weakly positive
tumours with CYP26B1 moderate and strong expressing tumours
showed that there was a highly significant association with survival
(HR=1.465, 95%CI= 1.151–1.865, x2 = 9.832, p = 0.002). Mean
survival for the negative/weak tumours (n = 458) was 125 months
(95%CI=115–135 months) while the mean survival for the
moderate/strong group of tumours (n = 164) was 96 months
(95%CI=108–124 months). CYP26B1 negative/weak/moderate
expressing tumours when compared with CYP26B1 strongly
expressing tumours also showed a highly significant association
with survival (HR=1.737, 95%CI=1.248–2.418, x2 = 11.092,
p = 0.001). The mean survival for the CYP26B1 negative/weak/
moderate group (n= 564) was 119 months (95%CI=111–128
months) whereas the mean survival for CYP26B1 strong tumours
(n = 58) was 80 months (95%CI= 60–101 months).
For LRAT there was a significant relationship with survival
(HR=1.321, 95%CI= 1.034–1.688, x2 = 5.039, p= 0.025) when
the immunohistochemistry intensity score were dichotomised into
LRAT negative and weak cases (n = 239) versus LRAT moderate
and strong cases (n = 383) (figure 5). For LRAT negative and weak
cases mean survival was 132 months (95%CI=119–146 months)
while for LRAT moderate and strong cases mean survival was 106
months (95%CI= 96–116 months). There was no association
between CYP26A1 and survival in the whole patient cohort.
The detailed relationship between CYP26A1, CYP26B1 and
LRAT expression, pathological parameters and overall survival is
shown in Tables S2, S3, S4, and S5.
In multivariate analysis CYP26B1 remained independently
prognostic (p = 0.026) while there was no independent prognostic
significance of LRAT expression (table 5). If the multivariate
analysis model contains only the variables that would be available
from a biopsy of colorectal cancer (i.e. no information regarding
pT stage, pN stage and EMVI) then CYP26B1 is a significant
independent prognostic marker (p = 0.017, Table S6).
MMR proficient cohort. In MMR proficient tumours there
was a consistent relationship between the intensity of CYP26B1
expression and overall survival (table 6, figure 4). Increasing
intensity of CYP26B1 immunoreactivity was associated with poorer
prognosis (HR=1.330, 95%CI=1.173–1.509, x2 = 21.493,
p,0.001). For CYP26B1 negative tumours (n = 200) the mean
survival was 143 months (95%CI= 127–158 months), for
CYP26B1 weak tumours (n = 186) the mean survival was 106
months (95%CI= 94–116 months), for CYP26B1 moderate
tumours (n = 87) the mean survival was 96 months
(95%CI=82–112 months) and for strongly expressing CYP26B1
tumours (n = 49) the mean survival was 77 months (95%CI 56–
98 months).
Comparing CYP26B1 negative tumours with tumours that
showed any CYP26B1 immunoreactivity then poorer survival was
associated with CYP26B1 expression (HR=1.604, 95%CI=
1.207–2.132, x2 = 10.796, p= 0.001). For CYP26B1 negative
tumours (n = 200) the mean survival was 143 months
(95%CI=127–158 months) while for CYP26B1 positive tumours
(n = 322) the mean survival was 104 months (95%CI= 94–114
months). Comparing CYP26B1 negative and weakly positive
tumours with CYP26B1 moderate and strong expressing tumours
showed a highly significant association with survival (HR=1.617,
95%CI=1.242–2.105, x2 = 12.962, p,0.001). Mean survival for
the negative/weak tumours (n = 386) was 130 months
(95%CI=120–141 months) and the mean survival for the
moderate/strong group of tumours was 92 months
(95%CI=79–106 months). CYP26B1 negative/weak/moderate
expressing tumours when compared with CYP26B1 strongly
expressing tumours also showed a highly significant association
with survival (HR=1.948, 95%CI= 1.366–2.777, x2 = 14.149,
p,0.001). The mean survival for the CYP26B1 negative/weak/
moderate group (n= 473) was 123 months (95%CI= 113–132
months) and the mean survival for CYP26B1 strongly expressing
tumours was 77 months (95%CI= 56–98 months).
For LRAT there was a significant relationship with survival
(HR=1.464, 95%CI= 1.110–1.930, x2 = 7.425, p = 0.006) when
the immunohistochemistry intensity scores were dichotomised into
LRAT negative and weak cases (n = 198) versus LRAT moderate
and strong cases (n = 326) (figure 5). For LRAT negative and weak
cases mean survival was 139 months (95%CI= 124–156 months)
while for LRAT moderate and strong cases mean survival was 106
months (95%CI= 96–116 months). There was no association
between CYP26A1 and survival in the MMR proficient patient
cohort.
In multivariate analysis CYP26B1 remained independently
prognostic (p = 0.026) while there was no independent prognostic
significance of LRAT expression (table 7). If the multivariate
analysis model contains only the variables that would be available
from a biopsy of colorectal cancer (i.e. no information regarding
tumour stage, nodal stage and extra-mural venous invasion) then
CYP26B1 is a highly significant independent prognostic marker
(p = 0.001, Table S6).
There was no relationship of MMR defective tumours with
CYP26A1, CYP26B1 or LRAT expression and overall survival.
Discussion
Colorectal cancer is one of the commonest types of cancer
whose incidence is continuing to rise and while the molecular
events characterising the early stage of colorectal cancer develop-
ment have been described in detail there is still clear requirement
Table 5. Multivariate analysis of whole patient cohort.
Variable Wald value p-value Hazard ratio (95%CI)
Age 25.027 ,0.001 1.899 (1.477–2.442)
Gender 1.313 0.252 0.871 (0.687–1.103)
Tumour site 6.390 0.041 0.983 (0.713–1.909)
Tumour differentiation 4.469 0.035 0.603 (0.377–0.964)
Tumour (pT) stage 21.910 ,0.001 0.486 (0.234–1.010)
Nodal (pN) stage 68.015 ,0.001 0.255 (0.184–0.702)
EMVI 20.064 ,0.001 1.872 (1.423–2.463)
MMR status 0.245 0.620 0.921 (0.666–1.274)
CYP26B1 4.962 0.026 1.177 (1.020–1.216)
LRAT 0.482 0.487 0.663–1.216)
doi:10.1371/journal.pone.0090776.t005
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to identify, characterise and validate biomarkers of colorectal
cancer [4–6,12].
This study has defined the expression profile of the retinoic acid
metabolising enzymes CYP26A1, CYP26B1 and CYP26C1 which
are members of the P450 family of enzymes and LRAT in a large
cohort of well characterised colorectal cancers. The prognostic
significance of the expression of these retinoic acid metabolising
enzymes has also been established.
The P450s are a large group of NADP dependent hydroxylases
classified into families, sub-families and individual members
[31–34]. There are two distinct functional groups of P450s based
on their substrate specificity for either xenobiotics or endogenous
compounds. CYP1, CYP2 and CYP3 are the predominant
families involved in the metabolism of xenobiotics while other
families from CYP4 upwards are involved in the metabolism of
specific groups of biologically active endogenous compounds
including eicosanoids, steroid hormones, bile acids and vitamins
including vitamin A and D [35–42]. They have multiple
transcriptional and post-transcriptional regulatory mechanisms
[43]. The xenobiotic metabolising forms of P450 have been
extensively studied in tumours and many individual members have
been shown to be overexpressed in specific types of tumours most
notably CYP1B1 which has been shown to have increased
expression in a wide range of tumours [25,44–52]. The tumour
selective expression of P450 has been proposed as a therapeutic
target especially for P450 mediated pro-drug activation [51–57].
The P450s involved in endogenous compound metabolism have
generally received much less study in tumours with the exception
of those P450s involved in sex hormone (oestrogen and
testosterone) metabolism in relation to targets in breast and
prostate cancer respectively [58–60].
Structurally the P450s show greatest amino acid diversity at
their C-termini which is the hydrophilic component of the protein
in contrast to the N-terminus which is the most lipophilic
component of the protein. Given the marked C-terminal amino
acid variation and its hydrophilicity the use of peptides to the C-
terminus of individual P450 as immunogens to produce mono-
clonal antibodies to individual forms of P450 has proven for many
research groups including our own to be a highly efficient strategy
to develop individual form-specific P450 monoclonal and poly-
clonal antibodies [30,61,62].
In this study we have produced antibodies that are specific for
individual forms of the CYP26 family namely CYP26A1,
CYP26B1 and CYP26C1. All three CYP26 enzymes hydroxylate
retinoic acid and the most fully characterised is CYP26A1 which is
the predominant form involved in retinoic acid hydroxylation.
CYP26B1 and CYP26C1 are more recently identified members of
the CYP26 family and are less well characterised in comparison
with CYP26A1. CYP26C1 appears to have predominant but not
Table 7. Multivariate analysis of MMR proficient cases.
Variable Wald value p-value Hazard ratio (95%CI)
Age 26.009 ,0.001 2.045 (1.553–2.692)
Gender 3.381 0.068 0.782 (0.601–1.016)
Tumour site 4.108 0.128 0.946 (0.677–1.836)
Tumour differentiation 7.941 0.005 0.420 (0.230–0.768)
Tumour (pT) stage 15.314 0.002 0.510 (0.241–1.080)
Nodal (pN) stage 49.405 ,0.001 0.263 (0.181–0.690)
EMVI 14.120 ,0.001 1.808 (1.327–2.461)
CYP26B1 8.091 0.004 1.255 (1.073–1.467)
LRAT 1.969 0.161 0.787 (0.563–1.100)
Significant values are highlighted in bold.
doi:10.1371/journal.pone.0090776.t007
Figure 6. A schematic pathway indicating the interaction of retinoic acid metabolising enzymes in normal and metastatic colorectal
cancer cells. A. CYP26A1, CYP26B1 and LRAT expression are low in normal cells which result in the ‘‘correct’’ amount of retinoic acid and expression
of retinoic acid target genes to maintain and promote normal cell growth and differentiation. B. CYP26A1, CYP26B1 and LRAT show significant
overexpression in metastatic colorectal cancer cells potentially reducing retinoic acid levels and retinoic acid target gene transcription which in turn
significantly alters growth, differentiation and promotes a pro-metastatic phenotype. Stra6, stimulated by retinoic acid gene 6 receptor, this cell
surface receptor promotes the intracellular uptake of retinol; RDH, retinol dehydrogenase; RALDH, retinaldehyde dehydrogenase.
doi:10.1371/journal.pone.0090776.g006
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necessarily exclusive expression in specific regions of the brain
[22,23].
Colorectal cancers can be classified according to their micro-
satellite instability/MMR status and this represents a major
pathway of colorectal cancer development [63,64]. In this study
we found prognostic significance for CYP26B1 in both the whole
patient cohort and in those tumours which were defined as
microsatellite intact or stable. In contrast those tumours which
were MMR defective did not show any prognostic significance
suggesting that distinct regulatory mechanisms may be operating
in MMR proficient and MMR defective tumours.
The CYP26 enzymes have been proposed as anti-cancer drug
targets [65] and the increased expression of CYP26A1 and
CYP26B1 in colorectal cancer would suggest that these enzymes
may be relevant therapeutic targets in this type of tumours. Several
series of compounds based on different structural properties have
been synthesised that inhibit CYP26 [66–69]. These compounds
are highly selective for CYP26 and show high inhibitory activity
(nanomolar potency) towards CYP26A1. However, the inhibitory
activity of these compounds towards CYP26B1 and CYP26C1 has
not yet been evaluated. Epidemiological evidence has also
proposed targeting of retinoids and the retinoic acid pathways
for chemoprevention of colorectal cancer and the increased
expression of CYP26A1 and CYP26B1 in colorectal cancer would
indicate that targeting these enzymes may be a useful approach
[70–72].
This study also found increased expression of LRAT in primary
colorectal cancer compared with normal colonic epithelium. This
finding appears to contrast with previous studies of other tumour
types including bladder cancer [73], breast cancer [74] and
prostate cancer [75] which have suggested reduced LRAT
expression in cancer cells albeit in those studies relatively small
numbers of tumour samples were analysed and mainly biochem-
ical assays of whole tumour extracts were used resulting in the
assessment of an ‘‘average level’’ as tumour stroma and necrotic
tissue will have been included. There were significant associations
between LRAT expression in both the whole patient cohort and
MMR proficient tumours when the LRAT scores were dichot-
omised into negative/weak/moderate and strong. This association
was not as marked for other cut-off points and was less robust than
observed for CYP26B1 in terms of prognostic significances.
The major problem with most types of cancer, including
colorectal cancer, is metastatic disease and treatment is usually
targeted at metastasis although phenotypic assessment on which
treatment decisions are often made by analysis of primary tumour
specimens. In contrast to the well defined molecular events leading
to the development of colorectal cancer the pathways of metastasis
have received much less attention [76]. This study was designed to
include the assessment of phenotypic expression in both primary
tumours and their corresponding lymph node metastasis. It was
found that there was no difference in expression in CYP26A1 or
CYP26B1 between primary tumours and corresponding lymph
node metastasis. However, LRAT showed significant decrease in
expression in lymph node metastasis compared with the corre-
sponding primary tumours. This suggests both primary tumour
related factors and microenvironmental factors are involved in the
regulation of expression of these enzymes in metastasis of
colorectal cancer. The potential consequences of altered expres-
sion of CYP26A1, CYP26B1 and LRAT in metastatic colorectal
cancer cells and their contribution to a pro-metastatic phenotype
are outlined in figure 6.
In summary monoclonal antibodies to individual retinoic acid
metabolising enzymes have been developed that are effective on
formalin fixed wax embedded tissue and shown that the retinoic
acid metabolising enzymes CYP26A1, CYP26B1 and LRAT are
significantly overexpressed in colorectal cancer and that CYP26B1
and LRAT are significantly associated with prognosis both in the
total patient cohort and in those tumour which are MMR
proficient. CYP26B1 which was independently prognostic in a
multivariate model both in the whole patient cohort and in MMR
proficient tumours represents a new biomarker of colorectal
cancer and CYP26B1 may represent a novel drug target for this
type of tumour.
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